سعر نيمينريكس مسحوق فيال للعضل 2024

Nimenrix meningococcal ACWY conjugate vaccine, powder for solution for intramuscular injection (Pfizer/GSK Egypt listing).

• Active immunization of individuals from 6 weeks of age against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y.Population: From 6 weeks of age (per EMA)European Medicines Agency (EMA)

• Very common/common: injection-site pain/redness/swelling, fever, irritability, drowsiness, headache, loss of appetite, GI symptoms (age-dependent).International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to the active substances or to any excipient, or to tetanus toxoid (carrier).International label, same product · European Medicines Agency (EMA)

• Do not inject intravascularly. Postpone in acute severe febrile illness. Syncope can occur after vaccination; observe. Immunocompromised persons may have reduced response.International label, same product · European Medicines Agency (EMA)

• Limited data in pregnancy; use only if clearly needed after benefit-risk assessment.International label, same product · European Medicines Agency (EMA)
• It is unknown whether Nimenrix is excreted in human milk; benefit-risk assessment required.International label, same product · European Medicines Agency (EMA)

• Neisseria meningitidis group A polysaccharide: Induces bactericidal antibodies against N. meningitidis serogroups A, C, W-135 and Y.
• Neisseria meningitidis group C polysaccharide: Induces bactericidal antibodies against N. meningitidis serogroups A, C, W-135 and Y.
• Neisseria meningitidis group W-135 polysaccharide: Induces bactericidal antibodies against N. meningitidis serogroups A, C, W-135 and Y.
• Neisseria meningitidis group Y polysaccharide: Induces bactericidal antibodies against N. meningitidis serogroups A, C, W-135 and Y.